NZ502395A - 4-Benzodioxolyl substituted pyrrolidine-3-carboxylic acid derivatives useful as endothelin antagonists - Google Patents

4-Benzodioxolyl substituted pyrrolidine-3-carboxylic acid derivatives useful as endothelin antagonists

Info

Publication number
NZ502395A
NZ502395A NZ502395A NZ50239598A NZ502395A NZ 502395 A NZ502395 A NZ 502395A NZ 502395 A NZ502395 A NZ 502395A NZ 50239598 A NZ50239598 A NZ 50239598A NZ 502395 A NZ502395 A NZ 502395A
Authority
NZ
New Zealand
Prior art keywords
carboxylic acid
acid derivatives
derivatives useful
endothelin antagonists
substituted pyrrolidine
Prior art date
Application number
NZ502395A
Other languages
English (en)
Inventor
Steven A King
Steven J Wittenberger
Martin Winn
Steven A Boyd
Charles W Hutchins
Hwan-Soo Jae
Andrew S Tasker
Thomas W Von Geldern
Jeffrey A Kester
Bryan K Sorensen
Bruce G Szczepankiewicz
Kenneth J Henry
Gang Liu
Original Assignee
Abbott Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/905,913 external-priority patent/US6162927A/en
Application filed by Abbott Lab filed Critical Abbott Lab
Publication of NZ502395A publication Critical patent/NZ502395A/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/24—Oxygen or sulfur atoms
    • C07D207/26—2-Pyrrolidones
    • C07D207/263—2-Pyrrolidones with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to other ring carbon atoms
    • C07D207/27—2-Pyrrolidones with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to other ring carbon atoms with substituted hydrocarbon radicals directly attached to the ring nitrogen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/16—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Pyrrole Compounds (AREA)
NZ502395A 1997-08-04 1998-07-27 4-Benzodioxolyl substituted pyrrolidine-3-carboxylic acid derivatives useful as endothelin antagonists NZ502395A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US08/905,913 US6162927A (en) 1994-08-19 1997-08-04 Endothelin antagonists
US4895598A 1998-03-27 1998-03-27
PCT/US1998/015479 WO1999006397A2 (en) 1997-08-04 1998-07-27 Pyrrolidine-3-carboxylic acid derivatives and their use as endothelin antagonists

Publications (1)

Publication Number Publication Date
NZ502395A true NZ502395A (en) 2002-08-28

Family

ID=26726720

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ502395A NZ502395A (en) 1997-08-04 1998-07-27 4-Benzodioxolyl substituted pyrrolidine-3-carboxylic acid derivatives useful as endothelin antagonists

Country Status (16)

Country Link
EP (1) EP1003740A2 (pt)
JP (1) JP2001512119A (pt)
CN (1) CN1301264A (pt)
AU (1) AU748469B2 (pt)
BG (1) BG104216A (pt)
BR (1) BR9815296A (pt)
CA (1) CA2297894A1 (pt)
HU (1) HUP0003484A3 (pt)
IL (1) IL134175A0 (pt)
NO (1) NO20000542L (pt)
NZ (1) NZ502395A (pt)
PL (1) PL342500A1 (pt)
SK (1) SK1452000A3 (pt)
TR (4) TR200101233T2 (pt)
TW (1) TW552260B (pt)
WO (1) WO1999006397A2 (pt)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000004179A1 (en) * 1998-07-15 2000-01-27 Bristol-Myers Squibb Company Stereoselective reductive amination of ketones
TWI306760B (en) 2000-08-07 2009-03-01 Abbott Lab Use of an endothelin et-a receptor antagonist and orally delivered pharmaceutical composition comprising the same
JPWO2002051836A1 (ja) * 2000-12-27 2004-04-22 協和醗酵工業株式会社 ジペプチジルペプチダーゼ−ｉｖ阻害剤
JP2005503339A (ja) * 2001-04-11 2005-02-03 アボット・ラボラトリーズ 前立腺患者における健康関連クオリティオブライフ及び病気進行までの健康関連クオリティ適応時間の有利な調整
FR2874015B1 (fr) * 2004-08-05 2006-09-15 Sanofi Synthelabo Derives de n-(1h-indolyl)-1h-indole-2-carboxamides, leur preparation et leur application en therapeutique
FR2880625B1 (fr) * 2005-01-07 2007-03-09 Sanofi Aventis Sa Derives de n-(heteroaryl)-1h-indole-2-carboxamides, leur preparation et leur application en therapeutique
WO2007034406A1 (en) * 2005-09-22 2007-03-29 Actelion Pharmaceuticals Ltd Pyrrolidine-3-carboxylic acid amide derivatives and their use as inhibitors of renin
WO2009026517A2 (en) 2007-08-22 2009-02-26 Gilead Colorado, Inc. Therapy for complications of diabetes
WO2011114103A1 (en) 2010-03-18 2011-09-22 Biolipox Ab Pyrimidinones for use as medicaments
JO2998B1 (ar) 2010-06-04 2016-09-05 Amgen Inc مشتقات بيبيريدينون كمثبطات mdm2 لعلاج السرطان
EP2760845B1 (en) 2011-09-27 2016-11-16 Amgen Inc. Heterocyclic compounds as mdm2 inhibitors for the treatment of cancer
US10531655B2 (en) 2011-12-02 2020-01-14 The Regents Of The University Of California Reperfusion protection solution and uses thereof
US11407721B2 (en) 2013-02-19 2022-08-09 Amgen Inc. CIS-morpholinone and other compounds as MDM2 inhibitors for the treatment of cancer
MX368703B (es) 2013-02-28 2019-10-11 Amgen Inc Un inhibidor de mdm2 derivado de acido benzoico para el tratamiento del cancer.
US9758495B2 (en) 2013-03-14 2017-09-12 Amgen Inc. Heteroaryl acid morpholinone compounds as MDM2 inhibitors for the treatment of cancer
JOP20200296A1 (ar) 2013-06-10 2017-06-16 Amgen Inc عمليات صنع وأشكال بلورية من mdm2 مثبط
CN104262329A (zh) * 2014-10-22 2015-01-07 南京友杰医药科技有限公司 反式阿曲生坦的制备
WO2024022262A1 (zh) * 2022-07-25 2024-02-01 深圳信立泰药业股份有限公司 一种内皮素a(eta)受体拮抗剂化合物的盐及其制备方法和医药用途

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5013842A (en) * 1990-01-22 1991-05-07 Monsanto Company Synthesis of chiral pyrrolidine and piperidine glycosidase inhibitors
ATE219077T1 (de) * 1994-08-19 2002-06-15 Abbott Lab Endothelin antagoniste
HUP9902316A3 (en) * 1996-02-13 2001-12-28 Abbott Lab 4-(benzo-1,3-dioxolyl)-pyrrolidine-3-carboxylic acid derivatives as endothelin antagonists and pharmaceutical compositions containing them
US5618949A (en) * 1996-07-12 1997-04-08 Abbott Laboratories Process for synthesis of chiral cis- and trans-3-amino-4-substituted pyrrolidine compounds

Also Published As

Publication number Publication date
PL342500A1 (en) 2001-06-04
BR9815296A (pt) 2001-11-20
TW552260B (en) 2003-09-11
JP2001512119A (ja) 2001-08-21
WO1999006397A2 (en) 1999-02-11
EP1003740A2 (en) 2000-05-31
NO20000542D0 (no) 2000-02-02
CA2297894A1 (en) 1999-02-11
WO1999006397A3 (en) 1999-12-09
TR200000993T2 (tr) 2000-12-21
AU748469B2 (en) 2002-06-06
TR200101234T2 (tr) 2002-06-21
TR200101233T2 (tr) 2002-06-21
IL134175A0 (en) 2001-04-30
SK1452000A3 (en) 2001-05-10
BG104216A (bg) 2000-12-29
CN1301264A (zh) 2001-06-27
TR200501137T2 (tr) 2005-12-21
HUP0003484A3 (en) 2002-02-28
HUP0003484A2 (hu) 2002-01-28
NO20000542L (no) 2000-04-04
AU8592198A (en) 1999-02-22

Similar Documents

Publication Publication Date Title
NZ502395A (en) 4-Benzodioxolyl substituted pyrrolidine-3-carboxylic acid derivatives useful as endothelin antagonists
RS50485B (sr) Terapeutske kombinacije koje sadrže amplodipin i atorvastatin
HUP0001285A3 (en) Pyrrolidine derivatives as protease inhibitors, process for producing them and pharmaceutical compositions containing them
IL160755A (en) N - (2 - bromophenyl) - n' [((r) - 1 - (5 - trifluoromethyl - 2 - pyridyl) pyrrolidin - 3 - yl)] urea, pharmaceutical compositions comprising it and process for its preparation
HUP0001539A3 (en) 2-(1-iminoethylamino)ethyl-homocysteine, process for its preparation and pharmaceutical compositions containing the same
IL189359A0 (en) Novel process for the synthesis of 5 - (4 - fluorophenyl) - 1 - [2 - ((2r, 4r)- 4 - hydroxy - 6 - oxo -tetrahydro - pyran - 2 - yl) - ethyl] - 2 - isopropyl- 4 - phenyl - 1h - pyrrole - 3 - carboxylic acid phenylamide
NO2005009I1 (no) Emselex-Darifenacin-IUPAC-nabn: (S)-2-(1-Ä2-(2,3-dihydrobenzofuran-5-yl)etylÜ3-pyrrolidinylÜ-2,2-difenylacetamid
HUP0200396A3 (en) Gluckokinase activators, process for their preparation, pharmaceutical compositions containing them and their use
EP1932543A3 (en) Combination therapy for osteoporosis consisting of an estrogen agonist/antagonist and a growth hormone secretagogue
IL150550A0 (en) 1,3-disubstituted pyrrolidines as alpha-2-adrenoceptor antagonists
IL138568A0 (en) 1-[(1-substituted-4-piperidinyl) methyl] -4- piperidine derivative, process for the preparation thereof, pharmaceutical composition containing the same and intermediate therefor
IL143858A (en) 4-(aminomethyl)-piperidine benzamides, process for their preparation and pharmaceutical compositions containing them
HUP0002057A3 (en) Indazole amide compounds, process for producing them, pharmaceutical compositions containing them and their intermediers
HUP0102099A3 (en) Substituted 2-oxo-alkanoic acid-[2-(indol-3-yl)ethyl]amides, process for producing them and pharmaceutical compositions containing them
IT1287174B1 (it) Diaril-ciclometilenpirazoli farmacologicamente attivi,procedimento per prepararli e composizioni farmaceutiche che li contengono
HUP0202736A3 (en) Substituted aromatic-ring compounds, process for producing the same, and pharmaceutical compositions containing them and use thereof
HUP0100336A3 (en) Vla-4 antagonists, pharmaceutical compositions comprising them and process for preparing them
UA41978C2 (uk) N-метил-n-[(1s)-1-феніл-2-((3s)-3-гідроксипіролідин-1-іл)етил]-2,2- дифенілацетамід гідрохлорид, спосіб його отримання та фармацевтична композиція
HUP9801950A3 (en) 2-(arylphenyl-amino)-imidazoline derivatives, process for producing them and pharmaceutical compositions containing them
HUP0104308A3 (en) Amidino and guanidino azetidinone derivatives as tryptase inhibitors, process for their preparation, pharmaceutical compositions thereof and intermediates
ES2192789T3 (es) Derivados de hidrazono-benzazuleno, composiciones farmaceuticas y compuestos intermedios.
HUP0400889A3 (en) Processes for the preparation of (r)-alpha-(2,3-dimethoxyphenyl)-1-[2-(4-fluorophenyl)ethyl]-4-piperidinemethanol and pharmaceutical compositions containing the compound
HK1061843A1 (en) Process for cis-1-(2-(4-(6-methoxy-2-phenyl-1,2,3,4-tetrahydronape ethyl) pyrrolidine
PL375415A1 (en) Process for preparing 5-(4-fluorophenyl)-1-[2-((2r,4r)-4-hydroxy -6-oxo-tetrahydro-pyran-2-yl)ethyl]-2-isopropyl-4-phenyl-1h-pyrrole-3-carboxylic acid phenylamide
HUP9902316A3 (en) 4-(benzo-1,3-dioxolyl)-pyrrolidine-3-carboxylic acid derivatives as endothelin antagonists and pharmaceutical compositions containing them

Legal Events

Date Code Title Description
RENW Renewal (renewal fees accepted)
PSEA Patent sealed
RENW Renewal (renewal fees accepted)
RENW Renewal (renewal fees accepted)